Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · IEX Real-Time Price · USD
1.240
+0.010 (0.81%)
At close: Mar 28, 2024, 3:58 PM
1.250
+0.010 (0.81%)
After-hours: Mar 28, 2024, 4:59 PM EDT
Company Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. is based in EmeryVille, California.
Estrella Immunopharma, Inc.
Country | United States |
Founded | 2021 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Cheng Liu Ph.D. |
Contact Details
Address: 5858 Horton Street, Suite 370 Emeryville, California 94608 United States | |
Phone | (510) 318-9098 |
Website | estrellabio.com |
Stock Details
Ticker Symbol | ESLA |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001844417 |
ISIN Number | US2975841048 |
Employer ID | 86-1314502 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Cheng Liu Ph.D. | Chief Executive Officer, President and Director |
Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 424B3 | Prospectus |
Mar 11, 2024 | 8-K | Current Report |
Mar 7, 2024 | 424B3 | Prospectus |
Mar 7, 2024 | 8-K | Current Report |
Feb 16, 2024 | 424B3 | Prospectus |
Feb 14, 2024 | 10-Q | Quarterly Report |
Feb 12, 2024 | 424B3 | Prospectus |
Feb 2, 2024 | 8-K | Current Report |
Jan 30, 2024 | 8-K | Current Report |
Dec 28, 2023 | EFFECT | Notice of Effectiveness |